<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666741</url>
  </required_header>
  <id_info>
    <org_study_id>HVT-R18-IND</org_study_id>
    <nct_id>NCT03666741</nct_id>
  </id_info>
  <brief_title>Inspiris Resilia Durability Registry</brief_title>
  <acronym>INDURE</acronym>
  <official_title>Clinical Outcomes of Patients Under the Age of Sixty Undergoing INSPIRIS RESILIA Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-label, multicenter, European registry with a follow-up of 5 years to assess
      the clinical outcomes of patients younger than 60 years who undergo surgical AVR with the
      INSPIRIS RESILIA Aortic Valve™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The INSPIRIS RESILIA Aortic Valve™ is a stented tri-leaflet valve comprised of bovine
      pericardial tissue. The tissue is created by treating bovine pericardial tissue with Edwards
      Integrity Preservation. It incorporates a stable capping anticalcification process, which
      blocks residual aldehyde groups known to bind with calcium. Tissue preservation with glycerol
      allows the valve to be stored without a traditional liquid-based solution, such as
      glutaraldehyde. Therefore, valve is stored under dry packaging conditions and consequently
      does not require rinsing prior to implantation.

      The novel tissue preservation technology significantly improves hemodynamic and
      anticalcification properties compared with the standard Perimount valve in an ovine model. In
      this registry, data is collected over a period of 5 years to demonstrate these properties in
      a clinical real-life setting. Clinical outcomes, hemodynamic as well as safety parameters and
      quality of life data are documented into e-CRF at baseline, surgery, pre-discharge, 3-6
      months and annually up to year 5.

      The required sample size was calculated using the online calculator at
      http://www.surveysystem.com/sscalc.htm. It was estimated, from COMMENCE Trial dataset that
      freedom from time-related valve safety events at 1 year (composite endpoint according to
      VARC-2) is around 0.915. The following table illustrates 95% CIs at different levels of risk:

      Sample Size Observed freedom from event 95%CI 400 0.900 ± 0.0294 400 0.910 ± 0.0280 400 0.915
      ± 0.0214 400 0.920 ± 0.0266 400 0.930 ± 0.0250

      20% of registry sites will be monitored with 100% source data verification
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Time-related valve safety</measure>
    <time_frame>Year 1</time_frame>
    <description>Composite endpoint according to VARC-2 depicted as freedom from event:
SVD (structural valve deterioration)
Valve-related dysfunction
Requirement of repeat procedure
Prosthetic valve endocarditis
Prosthetic valve thrombosis
Thromboembolic events (e.g. stroke)
Valve-related VARC bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from severe SVD (structural valve deterioration)</measure>
    <time_frame>Year 5</time_frame>
    <description>Freedom from stage 3 SVD including stenosis and regurgitation determined by echocardiography</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVR with or without CABG</intervention_name>
    <description>Surgical aortic valve implantation with INSPIRIS RESILIA Aortic Valve™</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under the age of 60 with an indication for surgical AVR who will receive an
        Edwards INSPIRIS RESILIA aortic valve prosthesis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 60 years inclusive

          2. Subject requiring a planned replacement of their native aortic valve as indicated in a
             preoperative evaluation

          3. Subject is scheduled to undergo planned aortic valve replacement with or without
             concomitant root replacement and/or coronary bypass surgery

          4. Subject is scheduled to attend yearly follow-up visits at the registry center up to 5
             years follow-up

          5. Subject provides written informed consent prior to the procedure

        Exclusion Criteria:

          1. Active endocarditis/myocarditis or endocarditis/myocarditis within 3 months prior to
             the scheduled aortic valve replacement surgery

          2. Previous aortic valve replacement

          3. Valve implantation is not possible in accordance with the device IFU

          4. Subject has a life expectancy ≤ 12 months for any reason

        Intraoperative Exclusion criteria:

        1. Valve implantation is not possible in accordance with the device IFU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bramlage, Professor</last_name>
    <role>Study Director</role>
    <affiliation>CEO IPPMed</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruggero dePaulis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Hospital Rome, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bart Meuris, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beate Botta, PhD</last_name>
    <phone>+49 4471 85033</phone>
    <phone_ext>25</phone_ext>
    <email>beate.botta@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Lüske, PhD</last_name>
    <phone>+49 4471 85033</phone>
    <phone_ext>24</phone_ext>
    <email>claudia.lueske@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KU Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Meuris, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU - Hospital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Bourguignon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart Center Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Borger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>European Hospital Rome</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruggero de Paulis, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Flameng W, Hermans H, Verbeken E, Meuris B. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015 Jan;149(1):340-5. doi: 10.1016/j.jtcvs.2014.09.062. Epub 2014 Sep 28.</citation>
    <PMID>25439467</PMID>
  </reference>
  <reference>
    <citation>Puskas JD, Bavaria JE, Svensson LG, Blackstone EH, Griffith B, Gammie JS, Heimansohn DA, Sadowski J, Bartus K, Johnston DR, Rozanski J, Rosengart T, Girardi LN, Klodell CT, Mumtaz MA, Takayama H, Halkos M, Starnes V, Boateng P, Timek TA, Ryan W, Omer S, Smith CR; COMMENCE Trial Investigators. The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue. Eur J Cardiothorac Surg. 2017 Sep 1;52(3):432-439. doi: 10.1093/ejcts/ezx158.</citation>
    <PMID>28605428</PMID>
  </reference>
  <reference>
    <citation>Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB; Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. EuroIntervention. 2012 Nov 22;8(7):782-95. doi: 10.4244/EIJV8I7A121.</citation>
    <PMID>23022744</PMID>
  </reference>
  <reference>
    <citation>Dvir D, Bourguignon T, Otto CM, Hahn RT, Rosenhek R, Webb JG, Treede H, Sarano ME, Feldman T, Wijeysundera HC, Topilsky Y, Aupart M, Reardon MJ, Mackensen GB, Szeto WY, Kornowski R, Gammie JS, Yoganathan AP, Arbel Y, Borger MA, Simonato M, Reisman M, Makkar RR, Abizaid A, McCabe JM, Dahle G, Aldea GS, Leipsic J, Pibarot P, Moat NE, Mack MJ, Kappetein AP, Leon MB; VIVID (Valve in Valve International Data) Investigators. Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. Circulation. 2018 Jan 23;137(4):388-399. doi: 10.1161/CIRCULATIONAHA.117.030729. Review.</citation>
    <PMID>29358344</PMID>
  </reference>
  <reference>
    <citation>Capodanno D, Petronio AS, Prendergast B, Eltchaninoff H, Vahanian A, Modine T, Lancellotti P, Sondergaard L, Ludman PF, Tamburino C, Piazza N, Hancock J, Mehilli J, Byrne RA, Baumbach A, Kappetein AP, Windecker S, Bax J, Haude M. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2017 Sep 1;52(3):408-417. doi: 10.1093/ejcts/ezx244.</citation>
    <PMID>28874031</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Valve Diseases</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Surgical valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

